文献速递冠心病血脂与心血管预防

匹伐他汀联合依折麦布强化降脂对急性冠脉综合征合并血脂异常患者的靶向治疗:HIJ-PROPER研究

Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomized trial.
PubMed 文献 · Eur Heart J · 2017-01-01

HIJ-PROPER研究是一项前瞻性、开放标签、随机试验,纳入1734例急性冠脉综合征合并血脂异常患者,比较匹伐他汀联合依折麦布强化降低LDL-C(目标<70 mg/dL)与匹伐他汀单药标准降脂(目标90-100 mg/dL)对心血管事件的影响。中位随访3.86年,两组主要终点发生率无显著差异(32.8% vs 36.9%,HR 0.89,95%CI 0.76-1.04,P=0.152)。在基线谷固醇升高的高胆固醇吸收患者中,联合治疗组主要终点发生率显著降低(HR 0.71,95%CI 0.56-0.91)。

要点

  • ACS合并血脂异常患者中,匹伐他汀联合依折麦布强化降脂未较单药标准治疗显著减少主要心血管事件。
  • 基线谷固醇升高的高胆固醇吸收患者中,联合治疗组主要终点发生率显著降低(HR 0.71)。
  • 研究结论需进一步确认。

核心结论

  • 在ACS合并血脂异常患者中,标准剂量匹伐他汀联合依折麦布强化降低LDL-C未较匹伐他汀单药标准降脂带来更多心血管获益。
  • 对于胆固醇吸收较高的患者,他汀联合依折麦布可能比他汀单药更有效,需进一步确认。

研究设计与样本

  • HIJ-PROPER研究为前瞻性、开放标签、随机对照试验,2010年1月至2013年4月在日本19家医院纳入1734例急性冠脉综合征合并血脂异常患者。
  • 患者随机分入强化降脂组(目标LDL-C<70 mg/dL,匹伐他汀联合依折麦布)或标准降脂组(目标LDL-C 90-100 mg/dL,匹伐他汀单药),随访至少36个月,中位随访3.86年。

主要发现

  • 随访期间平均LDL-C:匹伐他汀联合依折麦布组为65.1 mg/dL,匹伐他汀单药组为84.6 mg/dL。
  • 主要终点(全因死亡、非致死性心肌梗死、非致死性卒中、不稳定型心绞痛及缺血驱动血运重建的复合终点)发生率:联合治疗组283/864(32.8%),单药组316/857(36.9%),HR 0.89,95%CI 0.76-1.04,P=0.152。
  • 在基线谷固醇升高的高胆固醇吸收患者中,他汀联合依折麦布组主要终点发生率显著降低(HR 0.71,95%CI 0.56-0.91)。

临床怎么用

  • 在ACS合并血脂异常患者中,标准剂量匹伐他汀联合依折麦布强化降脂未较匹伐他汀单药标准降脂显著减少主要心血管事件。
  • 对于胆固醇吸收较高的患者,他汀联合依折麦布可能比他汀单药更有效,需进一步确认。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: To elucidate the effects of intensive LDL-C lowering treatment with a standard dose of statin and ezetimibe in patients with dyslipidaemia and high risk of coronary events, targeting LDL-C less than 70 mg/dL (1.8 mmol/L), compared with standard LDL-C lowering lipid monotherapy targeting less than 100 mg/dL (2.6 mmol/L). METHODS AND RESULTS: The HIJ-PROPER study is a prospective, randomized, open-label trial to assess whether intensive LDL-C lowering with standard-dose pitavastatin plus ezetimibe reduces cardiovascular events more than standard LDL-C lowering with pitavastatin monotherapy in patients with acute coronary syndrome (ACS) and dyslipidaemia. Patients were randomized to intensive lowering (target LDL-C < 70 mg/dL [1.8 mmol/L]; pitavastatin plus ezetimibe) or standard lowering (target LDL-C 90 mg/dL to 100 mg/dL [2.3-2.6 mmol/L]; pitavastatin monotherapy). The primary endpoint was a composite of all-cause death, non-fatal myocardial infarction, non-fatal stroke, unstable angina, and ischaemia-driven revascularization. Between January 2010 and April 2013, 1734 patients were enroled at 19 hospitals in Japan. Patients were followed for at least 36 months. Median follow-up was 3.86 years. Mean follow-up LDL-C was 65.1 mg/dL (1.68 mmol/L) for pitavastatin plus ezetimibe and 84.6 mg/dL (2.19 mmol/L) for pitavastatin monotherapy. LDL-C lowering with statin plus ezetimibe did not reduce primary endpoint occurrence in comparison with standard statin monotherapy (283/864, 32.8% vs. 316/857, 36.9%; HR 0.89, 95% CI 0.76-1.04, P = 0.152). In, ACS patients with higher cholesterol absorption, represented by elevated pre-treatment sitosterol, was associated with significantly lower incidence of the primary endpoint in the statin plus ezetimibe group (HR 0.71, 95% CI 0.56-0.91). CONCLUSION: Although intensive lowering with standard pitavastatin plus ezetimibe showed no more cardiovascular benefit than standard pitavastatin monotherapy in ACS patients with dyslipidaemia, statin plus ezetimibe may be more effective than statin monotherapy in patients with higher cholesterol absorption; further confirmation is needed. TRIAL NO: UMIN000002742, registered as an International Standard Randomized Controlled Trial.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Hagiwara N, Kawada-Watanabe E, Koyanagi R, et al. Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomized trial. Eur Heart J. 2017. PMID: 28430910. doi:10.1093/eurheartj/ehx162

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。